Toll-like receptor 2 and Toll-like receptor 4-MD-2 complex (TLR2/TLR4-MD-2)

Toll-like receptor 2 (TLR2) and the Toll-like receptor 4-MD-2 (TLR4-MD-2) complex are essential pattern recognition receptors (PRRs) that initiate innate immune responses by detecting pathogen-associated molecular patterns (PAMPs). TLR2, often functioning as a heterodimer with TLR1 or TLR6, recognizes a broad range of microbial products including lipoteichoic acid and peptidoglycan from Gram-positive bacteria (UniProt P67948). TLR4 requires the accessory protein MD-2 (Lymphocyte antigen 96) to sense lipopolysaccharide (LPS) from Gram-negative bacteria, triggering signaling through MyD88 and TRIF pathways (UniProt O00206, Q9Y6Y9). These receptors play pivotal roles in the pathogenesis of sepsis, where overactivation leads to a "cytokine storm," as well as in chronic inflammatory conditions like rheumatoid arthritis and atherosclerosis (Kawai & Akira, 2011). In oncology, TLR agonists are employed as vaccine adjuvants to stimulate robust T-cell responses against tumor antigens (Adams, 2009). Therapeutic development includes TLR4 antagonists like Eritoran for sepsis and TLR2-specific antibodies like Tomaralimab for ischemia-reperfusion injury (Opitz et al., 2010). Managing these targets requires careful balance to avoid systemic immunosuppression or excessive inflammatory toxicity. The dual targeting of these receptors is often explored to provide broader coverage against both Gram-positive and Gram-negative bacterial insults. Small molecules like Sparstolonin B have demonstrated the ability to inhibit both TLR2 and TLR4, offering a potential multi-pronged approach to treating complex inflammatory states. Overall, these receptors represent a cornerstone of immunology and a high-priority area for drug discovery in infectious and inflammatory diseases.

Other names

TLR2TLR4CD282CD284LY96MD-2Pattern recognition receptorsToll-like receptor 2Toll-like receptor 4Lymphocyte antigen 96

Agonists bind to the extracellular domains to induce receptor dimerization and recruitment of adapter proteins (MyD88/TRIF), while antagonists competitively inhibit ligand binding or prevent functional complex formation to suppress downstream pro-inflammatory signaling (O'Neill et al., 2013).